$20MSeries A, 21 January 2026
Series A first closing to take lead vaccine ErVac01 into clinical development; round stays open.
- Amount
- $20M
- Stage
- Series A
- Announced
- 21 January 2026
- Lead
- Seventure Partners
- Other investors
- SPRIM Global Investments
- Use of funds
- Series A first closing to take lead vaccine ErVac01 into clinical development; round stays open.
- Checked
- Announced by the company
- Sources
- ErVimmune raises EUR 17M Series A first close for its cancer vaccine seventure.fr
ErVimmune raises EUR 17M Series A first close for its cancer vaccine mypharma-editions.com